Get started
Author

Dawn Swan

CAR-T cell therapy in Multiple Myeloma: current status and future challenges
2024 · Dawn Swan, Deepu Madduri, et al. · Blood Cancer Journal · 115
PDF
Thrombosis in immune thrombocytopenia — current status and future perspectives
2021 · Dawn Swan, Adrian Newland, et al. · British Journal of Haematology · 74
PDF
Venous thromboembolism in multiple myeloma – choice of prophylaxis, role of direct oral anticoagulants and special considerations
2018 · Dawn Swan, Alberto Rocci, et al. · British Journal of Haematology · 64
PDF
Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma
2020 · Dawn Swan, Mark Gurney, et al. · HemaSphere · 58
Anticoagulation in chronic kidney disease: current status and future perspectives
2023 · Alfred Jones, Dawn Swan, et al. · Journal of Thrombosis and Haemostasis · 55
PDF
Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety
2023 · Dawn Swan, Philip Murphy, et al. · Cancers · 46
PDF
Management of bleeding and procedures in patients on antiplatelet therapy
2019 · Dawn Swan, Niamh Loughran, et al. · Blood Reviews · 31
The problem of under-diagnosis and over-diagnosis of pulmonary embolism
2019 · Dawn Swan, Sophy Hitchen, et al. · Thrombosis Research · 31
Non‐factor therapies for bleeding disorders: A primer for the general haematologist
2022 · Dawn Swan, Johnny Mahlangu, et al. · eJHaem · 29
Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis
2021 · Serika D Naicker, Claire L Feerick, et al. · OncoImmunology · 22
PDF
Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019
2022 · Dawn Swan, Patrick J. Hayden, et al. · British Journal of Haematology · 21
Practical management of the haemorrhagic complications of myeloproliferative neoplasms
2022 · Edward Jones, Bryan Dillon, et al. · British Journal of Haematology · 19
The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies
2021 · Dawn Swan, David Routledge, et al. · British Journal of Haematology · 19
PDF
Air pollution and venous thromboembolism: current knowledge and future perspectives
2024 · Dawn Swan, Robert Turner, et al. · The Lancet Haematology · 18
Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma
2019 · Dawn Swan, Kevin Lynch, et al. · Therapeutic Advances in Hematology · 17
PDF
The prothrombotic tendency of metabolic-associated fatty liver disease
2023 · Dawn Swan, Ton Lisman, et al. · Journal of Thrombosis and Haemostasis · 16
PDF
Port removal in patients receiving emicizumab prophylaxis: A single centre experience and review of the literature
2021 · Dawn Swan, Sri Paran, et al. · Haemophilia · 16
The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide
2020 · Subhashis Sarkar, Sachin K. S. Chauhan, et al. · Cancer Immunology Immunotherapy · 16
Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14)
2019 · Dawn Swan, Caoimhe Delaney, et al. · Haematologica · 12
PDF
Heparin – Messias or Verschlimmbesserung?
2021 · Dawn Swan, Marc Carrier, et al. · Journal of Thrombosis and Haemostasis · 11
PDF
Sialofucosylation Enables Platelet Binding to Myeloma Cells via P-Selectin and Suppresses NK Cell-Mediated Cytotoxicity
2023 · Alessandro Natoni, Marina Cerreto, et al. · Cancers · 10
PDF
Management of venous thromboembolism in athletes
2020 · Dawn Swan, Luke Carter-Brzezinski, et al. · Blood Reviews · 10
How to undertake procedures while on antiplatelet agents: a hematologist's view
2024 · Dawn Swan, Robert Turner, et al. · Research and Practice in Thrombosis and Haemostasis · 8
Hypersialylation Protects Multiple Myeloma Cells from NK Cell-Mediated Immunosurveillance and This Can be Overcome By Targeted Desialylation Using a Sialyltransferase Inhibitor
2019 · John Daly, Subhashis Sarkar, et al. · Blood · 8
Vaccine-induced thrombosis and thrombocytopenia (VITT) in Ireland: A review of cases and current practices
2021 · D. Swan, H. Enright, et al. · Thrombosis Update · 7
PDF
Works count: 63
Citation count: 808
H-index: 16
I10-index: 22
Year
Topic
Type